Cong-Cong Wang, Xiao-Li Li, Ying Liu, Bin Liu, Yue-Liang Zheng, Gong-Zhang Su, Yan-Lin Li, Tong Du, Xue-Lu Zhao, Rui-Sheng Duan
Journal: Frontiers in immunology 2025;16():1545579
PMID: 40356916
OBJECTIVE
To investigate the clinical characteristics and mechanisms of muscle atrophy in myasthenia gravis (MG) patients who are double-seropositive with acetylcholine receptor (AChR) antibodies and low-density lipoprotein receptor-related protein 4 (LRP4) antibodies.
METHODS
The clinical data, imaging characteristics, treatment methods, and prognosis of one case of MG with AChR/LRP4 antibodies complicated by muscle atrophy were analyzed. Literature on anti-AChR/LRP4 antibodies double-seropositive MG with muscle atrophy were reviewed.
CONCLUSION
Clinically, anti-AChR/LRP4 antibodies double-seropositive MG is rare, often onset after middle age, more common in females, frequently involving bulbar muscles, severe symptoms, poor prognosis, and unrelated to thymoma. Muscle atrophy in MG is not only seen in muscle-specific tyrosine kinase (MuSK)-MG but also in AChR-MG and seronegative MG. The mechanism of muscle atrophy may be related to genetic, immune, and nutritional factors.
Copyright © 2025 Zheng, Su, Li, Du, Zhao, Wang, Liu, Liu, Duan and Li.
Full Text Sources:
Medical:
Miscellaneous:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.